Astellas Pharma (OTCMKTS:ALPMY) Stock Passes Above 50-Day Moving Average - Time to Sell?

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report)'s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $9.56 and traded as high as $9.58. Astellas Pharma shares last traded at $9.49, with a volume of 70,162 shares.

Astellas Pharma Price Performance

The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.80 and a current ratio of 1.04. The firm has a market capitalization of $17.54 billion, a P/E ratio of -44.04 and a beta of 0.27. The company has a 50-day moving average price of $9.54 and a 200-day moving average price of $9.76.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last posted its quarterly earnings results on Friday, April 25th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.12. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. The business had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.02 billion. On average, sell-side analysts predict that Astellas Pharma Inc. will post 0.42 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.